Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

unprecedented number of orphan receptors, and our addiction and high-risk bleeding programs advanced toward the clinic. Following the close of the quarter, we added over $17 million to our balance sheet, positioning Omeros to execute on a series of value-driving milestones during the remainder of 2013 and well into 2014."

Third Quarter and Recent Highlights

  • Reported U.S. and European regulators had accepted Omeros' OMS302 marketing applications for review. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery® product designed to maintain intraoperative mydriasis, prevent miosis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. Omeros is preparing for a planned commercial launch of OMS302 in the second half of 2014.
  • Announced that Omeros entered into a settlement agreement with Carolina Casualty Insurance Company, or, CCIC, dated October 2, 2013, related to CCIC's defense of, and coverage obligations owed to, Omeros and its chief executive officer and chairman, Dr. Demopulos, in previously settled litigation with Omeros' former chief financial officer. The settlement included a release of each party's respective claims in the insurance coverage lawsuit and payment by CCIC of $12.5 million to Omeros, which was received on October 24, 2013.
  • Reported positive clinical data from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia.  Omeros subsequently started a Phase 2 trial evaluating the drug in patients with schizophrenia and plans to start a Phase 2 trial in Huntington's disease in early 2014. OMS824 has received orphan drug designation from the
    '/>"/>

  • SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros to Present at the 12th Annual Needham Healthcare Conference
    3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
    11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... Oct. 30, 2014  Ardelyx, Inc. (NASDAQ: ... on cardio-renal, gastrointestinal and metabolic diseases, today announced ... results on Thursday, November 6, 2014. Following the ... live conference call and webcast at 4:30pm ET ... a business update. The live webcast ...
    (Date:10/30/2014)... On October 26th at the Mid ... leading applied stem cell research scientist Neil Riordan, ... talks on New Techniques for Enhancing Stem Cell ... Cells. , Dr. Riordan focused on historical medical ... AlphaGEMS that include: wound healing; inflammation and pain ...
    (Date:10/30/2014)... 30, 2014 James Sherley says he has ... tissue stem cell technology since his days as a principal ... in the late 1990’s. Sherley founded the ASCTC as ... holds all the intellectual property developed in Sherley’s research over ... Massachusetts Institute of Technology (MIT), and more recently as a ...
    (Date:10/30/2014)... 30, 2014 Avure Technologies celebrates a year ... newest member of its fleet of high volume High Pressure ... anniversary as we return to PackExpo this year, which is ... Las Vegas,” said Jeff Williams, CEO at Avure. “Sales of ... pleased to be meeting the challenges of market demand for ...
    Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
    ... VEGAS, Oct. 21 Altogen Biosystems announced the release ... reagent ( http://www.altogen.com/mirna.php ) in the company,s popular in ... Kit. This reagent is also compatible for in vivo ... and small proteins. The company also offers custom encapsulation ...
    ... Mass., Oct. 21 Sermo ( http://www.sermo.com ), the ... Sermo Report titled, " Physician Participation in the ESA ... participation rates in the FDA-required Erythropoiesis-Stimulating Agents (ESAs) risk ... to the results, 83% of Hematologists/Oncologists view the ESA ...
    ... Oct. 21 Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... nationwide and internationally, is pleased to announce that Chairman, CEO ... Operations, will appear for one hour live on "Go Rogue ...
    Cached Biology Technology:PEG-Liposome siRNA In Vivo Transfection Kit From Altogen Biosystems 2Sermo Report Indicates Possible Decline in Prescribing of Erythropoiesis-Stimulating Agents 2Cord Blood America Management Team to Appear on National VoiceAmerica Radio Network 2
    (Date:10/29/2014)... been blamed for increasing the risk of a ... history of schizophrenia, are widely accepted. Others, such ... parasite transmitted by soil, undercooked meat and cat ... new study by Gary Smith, professor of population ... School of Veterinary Medicine, used epidemiological modeling methods ...
    (Date:10/29/2014)... York City on September 19, 2014, leading geneticist and ... of Genome Sciences and Medicine at the University of ... of Tel Aviv University, was awarded the 2014 Lasker-Koshland ... to her honorary degree from TAU, Prof. King was ... Medicine, and for the past 18 years she has ...
    (Date:10/29/2014)... An innovative workflow reveals new research potential of the ... recently published article in the Biodiversity Data ... BOLD in tabular format and imported these into a ... Writting Tool (PWT). Data were used to study ... wasps from the Microgastrinae subfamily. , BOLD is originally ...
    Breaking Biology News(10 mins):Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2
    ... latest-generation DNA sequencing technology to become the first explorers ... "This project is one of the first attempts to ... than a single organism," says Nicole Gerardo, assistant professor ... we can understand how these ants have evolved to ...
    ... the Centers for Disease Control and Prevention (CDC) found ... by age of menarche and total number of lifetime ... over the course of a woman,s lifetime may influence ... this study are published in Cancer Epidemiology, Biomarkers ...
    ... We see the face of the Virgin Mary staring up ... portion of our meal for $37,000 on eBay. We believe in ... science offers a wealth of rational explanations for natural phenomena, we ... And we,ll even go to war to protect our delusions against ...
    Cached Biology News:Landmark project to map genomics of complex ant systems 22 reproductive factors are important predictors of death from ovarian cancer 22 reproductive factors are important predictors of death from ovarian cancer 3Our 'caveman logic' embraces ESP over evolution 2
    This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
    ... Dunbar (1994) • This book describes ... methods for preparing samples for protein ... radiometric and bioluminescence-enhanced detection systems are ... the detection and characterization of glycoprotein ...
    All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
    Human HAPLN1 MAb (Clone 316119) Protein Family: Hyaluronan (HA) & HA Binding Proteins, Proteoglycan Regulators...
    Biology Products: